Allurion Technologies, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
OTC.Pink
Allurion secured FDA PMA approval for its swallowable gastric balloon but reported a 53% revenue decline, going‑concern doubts, NYSE delisting proceedings, and tight liquidity as it restructures and pursues financings.
OTC.Pink
Allurion Technologies, Inc. has filed an amended annual report, restating its 2023 financial statements due to accounting errors and disclosing material weaknesses in internal controls, alongside a significant net loss and going concern warning.
OTC.Pink
Allurion Technologies, Inc. restates prior financial statements due to material weaknesses in internal controls, reporting a reduced net loss for 2024 but facing ongoing liquidity concerns and NYSE compliance challenges.
OTC.Pink
10-K: Allurion Technologies Navigates Weight Loss Market with FDA Submission Plans and Global Expansion
Allurion Technologies plans to submit its final FDA module after positive AUDACITY trial results, resumes sales in France, and explores combination therapies to combat obesity.
OTC.Pink
Allurion Technologies has filed an amendment to its annual report on Form 10-K to include previously omitted information regarding directors, executive officers, and corporate governance.
OTC.Pink
Allurion Technologies experienced a 17% year-over-year revenue decline in 2023, alongside a significant increase in net losses, as it continues to develop its weight loss platform.